Cuba’s Soberana 2 Vaccine Candidate Shows 62% Efficacy With 2 Doses
Nina Siena | Jun 22 2021, 12:09AM EDT
Cuba’s Soberana 2 vaccine, now concluding its late phase trials, is showing promise with a 62% efficacy upon completion of just two of its required three doses. State-run BioCubaFarma, which has a long history of developing, producing and exporting serums, has five vaccine candidates in the works of clinical trials. Soberana 2 will conclude its late phase trials and should have final results in a few weeks.
According to Al Jazeera, several countries like Argentina, Mexico, Venezuela and Jamaica have expressed interest in buying Cuba’s vaccines. As it is, Iran has already started its production phase of Soberana 2 earlier this year which forms part of its late-phase trials.
Meanwhile, authorities in Cuba are well on their way in administering one of its five experimental vaccines as part of “intervention studies”. The government is hopeful its Abdala vaccine will slow down the spread of the virus in the wake of an outbreak in the Carribean’s largest island.
Official data shows that since the en-masse experimental vaccination campaign, daily infection cases in the capital have now been cut in half with the help of stricter lockdown measures.
Vicente Vérez Bencomo, director of the state-run Finlay Vaccine Institute, who is also part of the team who developed Soberana 2 said they expect results to be superior.
On Saturday, Cuban President Miguel Diaz-Canel expressed his thoughts at the presentation of results on state-run television: “We know our government has not been able to provide this project all the funding it required, and nonetheless this is a result of global standing.”
More:
https://www.latintimes.com/cubas-soberana-2-vaccine-candidate-shows-62-efficacy-2-doses-475444
= new reply since forum marked as read